
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.
How can primary care physicians effectively incorporate glucagon-like peptide-1 (GLP-1) receptor agonists into a comprehensive obesity treatment plan? In the video above, Michael Crotty, MD, a general practitioner who specializes in obesity medicine, offers practical guidance on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan that complements lifestyle and behavioral interventions.
Dr Crotty is also the co-founder and clinical lead of






